摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-Cyano-3-phenylthiobenzenamine | 147696-60-4

中文名称
——
中文别名
——
英文名称
4-Cyano-3-phenylthiobenzenamine
英文别名
4-amino-2-phenylsulfanylbenzonitrile
4-Cyano-3-phenylthiobenzenamine化学式
CAS
147696-60-4
化学式
C13H10N2S
mdl
——
分子量
226.302
InChiKey
RMMCVPVNGDXOAJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    425.1±40.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    75.1
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-Cyano-3-phenylthiobenzenaminepotassium permanganate溶剂黄146 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.75h, 生成 N-(4-Cyano-3-phenylsulfonylphenyl)-3,3,3,-trifluoro-2-hydroxy-2-methyl propanamide
    参考文献:
    名称:
    N-Aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides:  KATP Potassium Channel Openers. Modifications on the Western Region
    摘要:
    A subset of antiandrogen compounds, the N-aryl-3,3,3-trinuoro-2-hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (K-ATP) and represent a new class of potassium channel openers (PCOs). A structure-activity relationship was carried out on the western region of this series with the goal of obtaining an activator of the ATP sensitive potassium channel suitable for use in the treatment of urge urinary incontinence. In particular three large 4-(N-aryl) substituents, the (N-phenyl-N-methylamino)sulfonyl, benzoyl, and 4-pyridylsulfonyl moieties, yielded non-antiandrogen, K-ATP potassium channel openers (39, 41, and 64, respectively) that are bladder selective in an in vivo rat model that simultaneously measures bladder contractions, heart rate, and blood pressure. Substitutions of the aryl rings of 41 and 64 gave several derivatives that also display selectivity in the in vivo rat model; however, none appear to offer a substantial advantage over 41 and 64. The PCO activity of 41 and 64 resides in the (S)-(-) enantiomers. ZD6169, 41(S), has been selected into development for the treatment of urge urinary incontinence.
    DOI:
    10.1021/jm960365n
  • 作为产物:
    描述:
    参考文献:
    名称:
    Efficient Discovery of Potent Anti-HIV Agents Targeting the Tyr181Cys Variant of HIV Reverse Transcriptase
    摘要:
    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that interfere with the replication of human immunodeficiency virus (HIV) are being pursued with guidance from molecular modeling including free-energy perturbation (FEP) calculations for protein inhibitor binding affinities. The previously reported pyrimidinylphenylamine 1 and its chloro analogue 2 are potent anti-HIV agents; they inhibit replication of wild-type HIV-1 in infected human T-cells with EC50 values of 2 and 10 nM, respectively. However, they show no activity against viral strains containing the Tyr181Cys (Y181C) mutation in HIV-RT. Modeling indicates that the problem is likely associated with extensive interaction between the dimethylallyloxy substituent and Tyr181. As an alternative, a phenoxy group is computed to be oriented in a manner diminishing the contact with Tyr181. However, this replacement leads to a roughly 1000-fold loss of activity for 3 (2.5 mu M). The present report details the efficient, computationally driven evolution of 3 to novel NNRTIs with sub-10 nM potency toward both wild-type HIV-1 and Y181C-containing variants. The critical contributors were FEP substituent scans for the phenoxy and pyrimidine rings and recognition of potential benefits of addition of a cyanovinyl group to the phenoxy ring.
    DOI:
    10.1021/ja2058583
点击查看最新优质反应信息

文献信息

  • Therapeutic amides
    申请人:Imperial Chemical Industries PLC
    公开号:US05272163A1
    公开(公告)日:1993-12-21
    Amides having formula I: ##STR1## wherein E, X, R.sup.2 and R.sup.3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the amides and pharmaceutical compositions containing them.
    酰胺具有以下化学式I:##STR1## 其中E、X、R.sup.2和R.sup.3的含义如规范中所述,并且其药学上可接受的盐和在体内可水解的酯,可用于治疗尿失禁。还提供了制备这些酰胺的方法和含有它们的药物组合物。
  • Method of preparing therapeutic amides
    申请人:Imperial Chemical Industries, PLC
    公开号:US05684198A1
    公开(公告)日:1997-11-04
    Amides having formula I: ##STR1## wherein E, X, R.sup.2 and R.sup.3 have the meanings given in the specification, and pharmaceutically acceptable salts and pharmaceutically acceptable in vivo hydrolysable esters thereof, which are useful in the treatment of urinary incontinence. Further provided are processes for preparing the aides and pharmaceutical compositions containing them.
    具有以下式子I的酰胺:##STR1## 其中E、X、R.sup.2和R.sup.3的含义如规范中所述,并且其药学上可接受的盐和药学上可接受的体内可水解酯,可用于治疗尿失禁。还提供了制备这些酰胺的过程和含有它们的制药组合物。
  • US5272163A
    申请人:——
    公开号:US5272163A
    公开(公告)日:1993-12-21
  • US5382598A
    申请人:——
    公开号:US5382598A
    公开(公告)日:1995-01-17
  • US5474999A
    申请人:——
    公开号:US5474999A
    公开(公告)日:1995-12-12
查看更多